Clinical Trials Insight: 700023106
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2008
At a glance
- Drugs NGD 4715 (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Neurogen Corporation
- 08 Jan 2008 Status changed from planning to completed.
- 08 Jan 2008 The follow-up portion of this study has been completed.
- 08 Nov 2007 Neurogen extended this study in order to explore NGD 4715's effects on lipid levels and potential drug-drug interactions.